SCHEMBL5329180

SCHEMBL5329180

O=C1NCc2cccc(-c3c[nH]c4ccccc34)c21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.55
AURKA O14965 7/20 0.55
PARP1 P09874 1/20 0.52
PRKCB P05771 4/20 0.49
PRKCA P17252 4/20 0.49
CDK4 P11802 3/20 0.49
CCND1 P24385 3/20 0.49
PRKD3 O94806 3/20 0.49
PRKCG P05129 3/20 0.49
PRKCH P24723 3/20 0.49
PRKCI P41743 3/20 0.49
PRKCE Q02156 3/20 0.49
PRKCQ Q04759 3/20 0.49
PRKCZ Q05513 3/20 0.49
PRKCD Q05655 3/20 0.49
PRKD1 Q15139 3/20 0.49
CDK1 P06493 2/20 0.49
SIRT2 Q8IXJ6 2/20 0.49
CCNB2 O95067 1/20 0.49
CCNE2 O96020 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775231 0.73 AURKA (0.61) KDRAURKAPARP1CDK1CA12
SCHEMBL1202543 0.72 IMPDH2 (0.63) PRKCBPRKCACDK4CCND1PRKD3
SCHEMBL8167094 0.72 CDK4 (0.68) KDRAURKAPRKCBPRKCACDK4
SCHEMBL28476173 0.71 CA1 (0.51) PRKCBPRKCACDK4CCND1PRKD3
SCHEMBL5328900 0.71 AURKA (1.00) KDRAURKAPARP1CDK1CDK2
SCHEMBL5333071 0.70 KDR (1.00) KDRAURKAPARP1CDK1CA12
SCHEMBL6016048 0.70 PRKCB (0.44) PRKCBPRKCACDK4CCND1PRKD3
SCHEMBL10438759 0.70 SIRT2 (0.58) PRKCBPRKCACDK4CCND1PRKD3
SCHEMBL28000551 0.70 AURKA (0.75) KDRAURKAPARP1CDK1CA12
SCHEMBL743601 0.69 PARP1 (1.00) KDRAURKAPARP1PIM1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US claimed
WO-2007047646-A2 SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-26 WO claimed
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US disclosed
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US disclosed
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US disclosed
WO-2007047646-A2 SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-26 WO disclosed
WO-2007047646-A2 SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders MAP3K20, MAP3K3, MAP3K19 KDR 1627/4885AURKA 669/4885PARP1 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.